Veterans Affairs Greater Los Angeles Healthcare System, Division of Thoracic Surgery, Los Angeles, CA, USA ; UCLA Division of Thoracic Surgery and Comprehensive Mesothelioma Program, Los Angeles, CA, USA.
Veterans Affairs Greater Los Angeles Healthcare System, Division of Thoracic Surgery, Los Angeles, CA, USA ; UCLA Division of Thoracic Surgery and Comprehensive Mesothelioma Program, Los Angeles, CA, USA ; Pacific Meso Center at the Pacific Heart, Lung and Blood Institute, Los Angeles, CA, USA.
Cancer Manag Res. 2015 Jan 23;7:51-63. doi: 10.2147/CMAR.S72814. eCollection 2015.
Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to control. Despite some benefit from using the multimodality-approach (surgery, combination chemotherapy and radiation), survival remains poor. However, current research produced a list of potential therapies. Here, we summarize significant new preclinical and early clinical developments in treatment of MPM, which include mesothelin specific antibody and toxin therapies, interleukin-4 (IL-4) receptor toxins, dendritic cell vaccines, immune checkpoint inhibitors, and gene-based therapies. In addition, several local modalities such as photodynamic therapy, postoperative lavage using betadine, and cryotherapy for local recurrence, have also shown to be effective for local control of disease.
恶性胸膜间皮瘤（MPM）是一种难以控制的罕见肿瘤。尽管采用多模态方法（手术、联合化疗和放疗）有一定益处，但生存仍然很差。然而，目前的研究产生了一系列潜在的治疗方法。在这里，我们总结了 MPM 治疗方面的重要新的临床前和早期临床进展，包括间皮素特异性抗体和毒素治疗、白细胞介素 4（IL-4）受体毒素、树突状细胞疫苗、免疫检查点抑制剂和基因治疗。此外，几种局部治疗方法，如光动力疗法、术后使用碘伏冲洗以及局部复发病灶的冷冻疗法，也已被证明对疾病的局部控制有效。
